Established care
Early disease modification stays central
Treat-to-target rheumatology with conventional DMARDs, biologics, or JAK inhibitors continues to control inflammation and protect your joints.
Systemic disease, coordinated care
Stem cell therapy for rheumatoid arthritis in Istanbul, Turkey
A rheumatology-coordinated program combining systemic or joint-specific cell therapy with DMARD continuity and transparent Istanbul pricing.
Conceptual biological visualization
Evidence status
What the evidence can support now
What we add
Systemic and local MSC strategies
We offer IV immune-modulation protocols and intra-articular treatment of a selected symptomatic joint for eligible patients.
What we won't promise
Durable remission or medication freedom
We won't promise remission, cartilage regrowth, or a safe reason to stop standard therapy. We keep you informed at every step.
A direct answer
The short answer
We offer MSC-based immune-modulation protocols for treatment-resistant rheumatoid arthritis, coordinated closely with your rheumatologist. A local joint injection and a systemic IV product answer different questions, and neither replaces your DMARDs, biologics, or JAK therapy. Results vary between patients and stem cell therapy is not a guaranteed cure.
Start with the phenotype
RA and osteoarthritis need different plans
Rheumatoid arthritis is systemic autoimmune synovitis; osteoarthritis is primarily degenerative. We match your protocol to the correct diagnosis.
Disease-modifying care stays central
Standard RA therapy prevents damage and disability — we build around it, not over it.
- Early rheumatology diagnosis and treat-to-target monitoring
- Conventional DMARDs, biologic DMARDs, or JAK inhibitors as appropriate
- Short, carefully managed glucocorticoid use when needed
- Physical and occupational therapy, exercise, vaccination, and cardiovascular risk care
- Orthopedic or hand-surgery input for selected irreversible structural problems
- 01
Disease activity
Swollen and tender joints, CRP or ESR, global assessment, and composite scores such as DAS28 or CDAI.
- 02
Structural damage
Ultrasound, radiographs, or MRI show synovitis, erosions, and cartilage change.
- 03
Extra-articular disease
Lung, heart, vessels, eyes, nerves, and blood can be involved.
- 04
Treatment resistance
We confirm diagnosis, adherence, dose, and alternative pain causes before calling RA truly refractory.
Product and route matter
Two distinct protocols, never blurred
Systemic immune modulation and a local joint injection ask different questions — we're precise about which one applies to you.
- 01
Systemic IV MSCs
Protocols explore immune signaling and disease activity in treatment-resistant RA.
Evidence boundaryWe treat this as an addition to, not a replacement for, disease modification.
- 02
Intra-articular MSCs
A local injection can target pain, synovitis, or structure in one joint.
Evidence boundaryA local knee result is never presented as proof of systemic RA control.
- 03
Cell-derived products
Secretome and extracellular vesicle approaches are earlier in translation.
Evidence boundaryNo approved exosome product exists for RA in the United States, and we're clear about that.
- 04
Hematopoietic transplantation
High-risk immune ablation and rescue is a separate, hospital-based transplant strategy.
Evidence boundaryNot equivalent to an outpatient stromal-cell infusion; we explain the difference upfront.
Indexed evidence ledger
Read the endpoint, not just the headline
We report product, route, comparator, disease activity, medication background, and durability for every study behind your protocol.
01 Allogeneic adipose-MSC phase Ib/IIa
Open study- Product
- IV allogeneic adipose-derived MSCs
- Study design
- Randomized placebo-controlled study, 53 participants
- Finding
- Primarily supported safety and tolerability with an efficacy trend.
- Limitation
- Small placebo arm; not yet sufficient for routine disease modification.
02 Intra-articular knee phase I/II
Open study- Product
- Local autologous bone-marrow MSC injection
- Study design
- Randomized triple-blind placebo study, 30 participants
- Finding
- Safe and well tolerated with local clinical trends.
- Limitation
- Trends were not sustained beyond 12 months and don't prove systemic RA control.
03 UC-MSC plus DMARD study
Open study- Product
- Umbilical-cord MSCs used with background DMARDs
- Study design
- Clinical study, 172 participants
- Finding
- Reported disease-activity signals.
- Limitation
- Doesn't establish broad durable remission or medication withdrawal.
Measure what changes
Outcomes that hold up to scrutiny
Pain alone can't distinguish active synovitis from established damage, tendon disease, or osteoarthritis — we measure precisely.
- 01
Disease activity
DAS28, CDAI or SDAI with tender and swollen joint counts.
- 02
Inflammation
CRP, ESR, ultrasound power Doppler, and clinician assessment in context.
- 03
Function
HAQ-DI, grip, work, sleep, fatigue, and patient-defined goals.
- 04
Durability and damage
Sustained response, flare rate, medication stability, and imaging over adequate follow-up.
Clinical review before travel
A rheumatology-led Istanbul evaluation
Your review separates active inflammatory disease from irreversible damage and non-inflammatory pain before we recommend a protocol.
Records to send
- Rheumatologist diagnosis and disease duration
- RF, anti-CCP, CRP, ESR, CBC, kidney and liver results
- DAS28 or other disease-activity record and recent imaging
- Complete DMARD, biologic, JAK, steroid, and response history
- Infection, vaccination, lung, heart, pregnancy, and malignancy history
Reasons to pause
- Active infection or inadequately evaluated fever
- Uncontrolled systemic disease or unstable organ involvement
- A plan to interrupt DMARD or biologic therapy without rheumatology agreement
- Any clinic marketing a local joint injection as a systemic cure
Transparent planning
Rheumatoid arthritis stem cell therapy cost in Turkey
Your quote distinguishes systemic IV planning from a local image-guided joint procedure and states clearly how rheumatology monitoring and medication coordination are handled.
For context, our general 2026 MSC planning range is $7,000-$18,000. Your RA-specific quote is itemized once your protocol is confirmed.
- Systemic versus local treatment question
- Exact product, source, dose, and release testing
- Number of joints and image guidance if local
- Rheumatology coordination, monitoring, and follow-up
Questions patients ask us
- 01
How much does RA stem cell therapy cost in Istanbul?
- 02
Is the goal systemic RA activity or one painful joint?
- 03
How many days should I plan to stay in Istanbul?
- 04
How will DMARDs, biologics, steroids, infection screening, and vaccination be coordinated?
Primary reading
Sources behind this guide
FAQ
Questions about rheumatoid arthritis
Some patients see meaningful disease-activity improvement in early studies alongside standard medication, but we don't promise predictable or durable remission. Results vary between patients and stem cell therapy is not a guaranteed cure.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.